2006
DOI: 10.1002/jso.20564
|View full text |Cite
|
Sign up to set email alerts
|

Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

Abstract: Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer. However, the side-effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third-generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
6
0
1

Year Published

2006
2006
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 25 publications
0
6
0
1
Order By: Relevance
“…The major toxicity associated with AIs including exemestane is joint pain and bone loss, the propensity for bone fractures, and increased risk for osteoporosis [1113], a pattern consistent with the lower hip and lumbar spine bone mineral density observed in patients on AIs [14]. Although not as severe as tamoxifen, other toxicities reported for AIs include a variety of gynecological events including vaginal bleeding or discharge and hot flashes [15,16]. Variability in changes to lipid profiles, manifestation of osteoporosis, and time of recurrence, were observed in patients in many AI clinical trials [9] and the mechanism underlying this variability in response to AIs and to their toxicities remains unclear.…”
Section: Introductionmentioning
confidence: 99%
“…The major toxicity associated with AIs including exemestane is joint pain and bone loss, the propensity for bone fractures, and increased risk for osteoporosis [1113], a pattern consistent with the lower hip and lumbar spine bone mineral density observed in patients on AIs [14]. Although not as severe as tamoxifen, other toxicities reported for AIs include a variety of gynecological events including vaginal bleeding or discharge and hot flashes [15,16]. Variability in changes to lipid profiles, manifestation of osteoporosis, and time of recurrence, were observed in patients in many AI clinical trials [9] and the mechanism underlying this variability in response to AIs and to their toxicities remains unclear.…”
Section: Introductionmentioning
confidence: 99%
“…ER positive status is generally associated with a more favorable prognosis (1,2), but more importantly, it is a predictive marker of response to hormonal therapies such as tamoxifen and aromatase inhibitors (3,4). However, ER-positive tumors represent a large and heterogeneous subgroup, and treatment decisions are most often based on clinicopathologic features such as tumor grade and lymph node status.…”
Section: Introductionmentioning
confidence: 99%
“…The use of AIs has been very successful in combating hormone sensitive breast cancer in postmenopausal women [19,95,96,[108][109][110]. However, the risk of these cancers developing resistance to the available therapeutics cannot be ignored.…”
Section: Resultsmentioning
confidence: 99%